Comparing the triad of DMARDs to the biologic therapy, the study demonstrated “similar clinical and radiologic results,” says Dr. O’Dell. In addition, he says the use of DMARDs could “save a half million dollars over a patient’s life time.”
Dr. O’Dell is chief of the University of Nebraska Medical Center Division of Rheumatology and Immunology and chief of rheumatology at the Omaha (Neb.) VA Medical Center.
Ann-Marie Lindstrom is an independent writer and editor based in the Tucson, Ariz., area.